Koosha Paydary, MD
Hematology & Oncology · Chicago, ILNPI 1194245514
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $8,625 of the $12,658 with a category attached, or 68.1%. 8 manufacturers reported payments, led by Bayer at 47.4% of the total. 2025 is the largest year on record at $12,270, more than ten times the $118 reported in 2021.
Across 29 payments — averaging $436.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$6K
- Partner Therapeutics, Inc.$4K
- Catalyst Pharmaceuticals, Inc.$2K
- Regeneron Healthcare Solutions, Inc.$188
- Exelixis Inc.$136
- Johnson & Johnson$113
- plus $133 from 2 others
Across 30 payments — averaging $1033.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Daiichi Sankyo Inc.$31K
What the payments were for
- Consulting fees$8,62568%
- Speaking & faculty fees$1,68813%
- Travel & lodging$1,1959%
- Food & beverage$1,1509%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 8 | $5,999 |
| Partner Therapeutics, Inc. | 11 | $4,263 |
| Catalyst Pharmaceuticals, Inc. | 3 | $1,826 |
| Regeneron Healthcare Solutions, Inc. | 2 | $188 |
| Exelixis Inc. | 2 | $136 |
| Johnson & Johnson | 1 | $113 |
| Novocure Inc. | 1 | $93 |
| Pfizer | 1 | $40 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,658 in reported general payments places this provider in the 75th percentile of 580 hematology & oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 24 | $410,428 |
| Fentanyl | 27 | $2,019 |
| Lidocaine Hcl ViscousLidocaine Hcl | 37 | $977 |
| Prochlorperazine Maleate | 69 | $785 |
| Dexamethasone | 76 | $718 |
| Gabapentin | 60 | $520 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 24 | $371 |
| Ondansetron Hcl | 58 | $297 |
| Mirtazapine | 14 | $237 |
| Oxycodone Hcl | 17 | $218 |
| Tramadol Hcl | 26 | $52 |
| Furosemide | 12 | $28 |
| Amlodipine Besylate | 11 | $20 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Chicago
- Michael BishopChicago$974K
- Jamile ShammoChicago$910K
- Young Kwang ChaeChicago$563K
- Irfan MirzaChicago$544K
- Marina GarassinoChicago$397K
- Chih-Yi LiaoChicago$317K
- Rita NandaChicago$286K
- Shuo MaChicago$280K
- Santosh SarafChicago$275K
- Peter RiedellChicago$273K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.